Uncategorized

Biogen, Denali pull plug on Parkinson’s program after mid-stage flop

Published

on

Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version